Akamizu T, Inoue D, Kosugi S, Kohn L D, Mori T
Department of Laboratory Medicine, Kyoto University School of Medicine, Japan.
Thyroid. 1994 Spring;4(1):43-8. doi: 10.1089/thy.1994.4.43.
Our previous study of chimeric TSH-LH/CG receptors showed that substituting amino acid residues 268-304 of the TSH receptor with homologous residues from the LH/CG receptor markedly decreased high affinity TSH binding as evidenced by ligand displacement assays [Akamizu et al. Endocr J 40:363-372, 1993]. Despite this change in TSH binding, there was a minimal change in TSH-stimulated activity in cAMP assays. To explain this dissociation of TSH binding and function, further characterization of individual residues within the 268-304 segment was performed. Five additional chimeric TSH-LH/CG receptors within this region were constructed by substituting corresponding residues of rat LH/CG receptor. After transfection in Cos-7 cells, TSH receptor activities of these chimeras were evaluated. A single point mutation of cysteine-301 to glutamate resulted in a mutant receptor that exhibited the same receptor bioactivity as the chimeric receptor with amino acids 268-304 substituted by LH/CG receptor residues: apparent low affinity TSH binding in ligand displacement assays but significant retention of the cAMP response to TSH. The four other chimeric substitutions yielded cDNAs coding for receptors that behaved like wild-type receptors. Western blot analyses using a TSH receptor-specific antibody showed that all five of the new mutants were synthesized and integrated in the membrane. These results suggest that cysteine-301 is the critical residue whose mutation accounts for the original chimeric results and the dissociation of binding and functional activity. The possibility must be considered that cysteine-301 is involved in disulfide bond formation and is important in tertiary structure and that conformational changes in the receptor result from its mutation.
我们之前对嵌合型促甲状腺激素(TSH)-促黄体生成素(LH)/绒毛膜促性腺激素(CG)受体的研究表明,用LH/CG受体的同源残基替换TSH受体的268-304位氨基酸残基,可显著降低高亲和力TSH结合,这在配体置换试验中得到了证实[赤水等人,《内分泌学杂志》40:363-372,1993年]。尽管TSH结合发生了这种变化,但在环磷酸腺苷(cAMP)试验中,TSH刺激的活性变化极小。为了解释TSH结合与功能的这种分离现象,我们对268-304片段内的各个残基进行了进一步表征。通过替换大鼠LH/CG受体的相应残基,在该区域构建了另外五个嵌合型TSH-LH/CG受体。在Cos-7细胞中进行转染后,评估了这些嵌合体的TSH受体活性。将半胱氨酸-301单点突变为谷氨酸,产生了一种突变受体,其表现出与用LH/CG受体残基替换268-304位氨基酸的嵌合受体相同的受体生物活性:在配体置换试验中表现为明显的低亲和力TSH结合,但对TSH的cAMP反应仍有显著保留。其他四个嵌合替换产生了编码行为类似于野生型受体的受体的cDNA。使用TSH受体特异性抗体进行的蛋白质印迹分析表明,所有五个新突变体均已合成并整合到膜中。这些结果表明,半胱氨酸-301是关键残基,其突变导致了最初的嵌合结果以及结合与功能活性的分离。必须考虑到半胱氨酸-301参与二硫键形成且对三级结构很重要,并且受体的构象变化是由其突变引起的可能性。